| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients.
Noxxon Pharma AG is a Germany-based biotechnology company with focus on cancer treatment. The Company develops drugs under the trademark Spiegelmer, which target the tumor microenvironment. Spiegelmers can be manufactured chemically and are a variant o...
Germiphene Corporation is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Veranova is a global leader in process development and manufacturing of active pharmaceutical ingredients (APIs), focused on specialty niches with expertise in highly regulated and complex chemistries. Veranova is headquartered in Wayne, PA and has operations in North America and Europe.